LB4. A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs. ABC/DTG/3TC in Treatment-Naïve Adults at Week 96

BACKGROUND: Bictegravir (B), a potent INSTI with a high barrier to resistance, is coformulated with emtricitabine (F) and tenofovir alafenamide (TAF) as the FDA-approved single-tablet regimen B/F/TAF. We report Week 96 results from an ongoing phase 3 study comparing B/F/TAF to coformulated dolutegra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohl, David A, Yazdanpanah, Yazdan, Baumgarten, Axel, Clarke, Amanda, Thompson, Melanie, Brinson, Cynthia, Hagins, Debbie, Ramgopal, Moti, Antinori, Andrea, Wei, Xuelian, White, Kirsten, Collins, Sean, Cheng, Andrew, Quirk, Erin, Martin, Hal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254103/
http://dx.doi.org/10.1093/ofid/ofy229.2178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254103/
http://dx.doi.org/10.1093/ofid/ofy229.2178

Ejemplares similares